Menlo Park, CA · Founded 2014 · Privately Held (backing)
Operator of a biomarker-driven precision medicine company intended to improve monitoring and treatment decisions for neurodegenerative diseases. Octave Bioscience is based in Menlo Park, CA and was founded in 2014. Its last reported valuation was $143 million in Jul 2023. It has raised $129 million across 5 recorded rounds; the latest was a $31.8 million early-stage round in Mar 2025.
Last reported valuation
$143.0M
Oct 2026
Priced at
—
Total raised
$129.2M
Last round
Early Stage VC
Mar 2025
No prints on record
No secondary trades in Octave Bioscience shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Octave Bioscience with a free account
·The complete investor list: 18 names
·Watch Octave Bioscience: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Octave Bioscience stock.
